Oropharynx Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ORP003 MIFTS: 50	Oropharynx Cancer Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer ¹¹ ¹⁴ ¹⁶

Oropharyngeal Cancer ¹¹ ⁵³ ¹⁴ ⁷⁵

Malignant Neoplasm of Oropharynx ⁷¹ ³¹

Oropharyngeal Carcinoma ¹¹ ⁷¹

Malignant Tumour of Mesopharynx ¹¹

Malignant Oropharyngeal Tumor ¹¹

Malignant Tumor of Oropharynx ¹¹

Oropharyngeal Cancer, Adult ¹⁹

Cancer of the Oropharynx ¹⁹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of lip, oral cavity and pharynx

Malignant neoplasm of oropharynx

Malignant neoplasm: Lateral wall of oropharynx

Malignant neoplasm: Oropharynx, unspecified

Malignant neoplasm: Overlapping lesion of oropharynx

Malignant neoplasm: Posterior wall of oropharynx

External Ids:

Disease Ontology ¹¹ DOID:8557

ICD9CM ³⁴ 146 146.5 146.6 more

NCIt ⁴⁹ C7398

SNOMED-CT ⁶⁸ 187686007 93933005 93971002

ICD10 ³¹ C10 C10.2 C10.3 more

EFO ¹⁶ EFO_1001931

UMLS ⁷¹ C0153382 C0153388 C0153389 more

Sources

Summaries for Oropharynx Cancer

GARD: ¹⁹ A primary or metastatic malignant neoplasm that affects the oropharynx.

MalaCards based summary: Oropharynx Cancer, also known as oropharyngeal cancer, is related to papilloma and laryngeal benign neoplasm. An important gene associated with Oropharynx Cancer is ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide), and among its related pathways/superpathways are Endometrial cancer and Malignant pleural mesothelioma. The drugs Mitomycin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the, tonsil and tongue, and related phenotype is integument.

Disease Ontology: ¹¹ A pharynx cancer that is located in the oropharynx.

Wikipedia: ⁷⁵ Oropharyngeal cancer (OPC), also known as oropharyngeal squamous cell carcinoma (OPSCC) and tonsil... more...

Sources

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)

#	Related Disease	Score	Top Affiliating Genes
1	papilloma	31.1	TP53 ERBB2 EGFR CDKN2A
2	laryngeal benign neoplasm	31.0	TP53 EGFR CDKN2A
3	pharynx cancer	30.9	MIR99A MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
4	cervical cancer	30.8	TP53 MIR93 MIR21 MIR196A1 ERBB2 CDKN2A
5	oral squamous cell carcinoma	30.7	MIR99A MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
6	hypopharynx cancer	30.7	TP53 EGFR CDKN2A CD274
7	head and neck cancer	30.7	TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
8	alcohol use disorder	30.6	SERPINA3 MIR196A1 H2AC18 ADH1C
9	keratinizing squamous cell carcinoma	30.6	TP53 EGFR CDKN2A
10	tongue carcinoma	30.6	TP53 MIR99A MIR21 EGFR CDKN2A
11	lip and oral cavity cancer	30.6	TP53 MIR21 KIT EGFR CDKN2A ADH1C
12	squamous cell carcinoma, head and neck	30.6	TP53 MIR99A MIR486-1 MIR21 MIR196A1 MIR193B
13	viral infectious disease	30.5	SERPINA3 MIR21 H2AC18 CD274
14	anogenital venereal wart	30.5	TP53 H2AC18 GP5 CDKN2A
15	anus cancer	30.5	TP53 H2AC18 GP5 ERBB2 EGFR CDKN2A
16	atypical teratoid rhabdoid tumor	30.3	TP53 H2AC18 EGFR CDKN2A
17	penile benign neoplasm	30.3	TP53 GP5 CDKN2A CD274
18	sweat gland cancer	30.3	TP53 MAML2 KIT ERBB2
19	skin squamous cell carcinoma	30.3	TP53 MIR21 ERBB2 EGFR CDKN2A
20	tonsil cancer	30.3	TP53 SERPINA3 NFIB MYBL1 MIR93 MIR193B
21	small cell cancer of the lung	30.3	TP53 MIR21 KIT EGFR CDKN2A
22	tonsil squamous cell carcinoma	30.3	MIR193B CDKN2A
23	adenocarcinoma	30.3	TP53 ERBB2 EGFR CDKN2A CD274
24	larynx cancer	30.3	TP53 MIR93 MIR486-1 MIR21 MIR196A1 EGFR
25	penile cancer	30.2	TP53 GP5 EGFR CDKN2A CD274
26	tongue squamous cell carcinoma	30.2	TP53 MIR99A MIR486-1 MIR21 MIR196A1
27	exanthem	30.2	KIT H2AC18 ERBB2 EGFR CD274
28	lymphatic system disease	30.2	TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
29	oral cavity cancer	30.2	MIR99A MIR93 MIR486-1 MIR21 MIR196A1 MIR193B
30	deficiency anemia	30.1	TP53 SERPINA3 MIR486-1 KIT H2AC18
31	interstitial lung disease 2	30.1	TP53 SERPINA3 MIR486-1 MIR21 MIR196A1 H2AC18
32	suppression of tumorigenicity 12	30.1	TP53 SERPINA3 H2AC18 ERBB2 EGFR CDKN2A
33	ovarian disease	30.1	TP53 MIR93 MIR486-1 MIR21 MIR193B H2AC18
34	meningioma, familial	30.1	TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
35	adenoid cystic carcinoma	30.1	TP53 SERPINA3 NFIB MYBL1 KIT ERBB2
36	esophageal cancer	30.1	TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
37	human papillomavirus infectious disease	30.1	TP53 MIR486-1 MIR21 MIR196A1 MIR193B GP5
38	tongue disease	30.0	TP53 MIR99A MIR486-1 MIR21 MIR196A1 MIR193B
39	myelodysplastic syndrome	30.0	TP53 KIT H2AC18 ERBB2 CDKN2A
40	nasopharyngeal carcinoma	30.0	TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
41	skin carcinoma	30.0	TP53 MIR21 KIT H2AC18 ERBB2 EGFR
42	lung squamous cell carcinoma	30.0	TP53 MIR93 MIR196A1 MIR193B H2AC18 EGFR
43	lung cancer susceptibility 3	30.0	TP53 MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
44	ovarian cancer	29.8	TP53 MIR99A MIR21 MIR196A1 KIT H2AC18
45	peripheral nervous system disease	29.8	TP53 SERPINA3 MIR486-1 MIR21 MIR196A1 KIT
46	leukemia, acute myeloid	29.6	TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
47	breast cancer	29.6	TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
48	connective tissue disease	29.6	TP53 SERPINA3 MIR99A MIR93 MIR486-1 MIR21
49	lung cancer	29.6	TP53 SERPINA3 MIR99A MIR93 MIR486-1 MIR21
50	cutaneous telangiectasia and cancer syndrome, familial	11.6

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):

Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:

Sources

Symptoms & Phenotypes for Oropharynx Cancer

MGI Mouse Phenotypes related to Oropharynx Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	integument	MP:0010771	9.28	CD274 CDKN2A EGFR ERBB2 KIT MIR193B

Sources

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Mitomycin

Approved

Phase 4

50-07-7

5746

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Fluorouracil

Approved

Phase 3

51-21-8

3385

Gabapentin

Approved, Investigational

Phase 3

60142-96-3

3446

Clonidine

Approved

Phase 2, Phase 3

4205-91-8, 4205-90-7

2803 20179

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Sucralfate

Approved

Phase 3

54182-58-0

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Durvalumab

Approved, Investigational

Phase 2, Phase 3

1428935-60-7

Cetuximab

Approved

Phase 3

205923-56-4

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Kava

Approved, Investigational, Nutraceutical

Phase 3

9000-38-8

Immunosuppressive Agents

Phase 3

Antimetabolites

Phase 3

Anti-Anxiety Agents

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Psychotropic Drugs

Phase 3

Anticonvulsants

Phase 3

Neurotransmitter Agents

Phase 2, Phase 3

Anti-Ulcer Agents

Phase 3

Antacids

Phase 3

Gastrointestinal Agents

Phase 3

Mitogens

Phase 2, Phase 3

Adrenergic alpha-Agonists

Phase 2, Phase 3

Adrenergic Agonists

Phase 2, Phase 3

Adrenergic Agents

Phase 2, Phase 3

Antihypertensive Agents

Phase 2, Phase 3

Analgesics

Phase 2, Phase 3

Sympatholytics

Phase 2, Phase 3

Aloe

Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Endothelial Growth Factors

Phase 2, Phase 3

Immunologic Factors

Phase 2, Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Hormones

Phase 3

Antimitotic Agents

Phase 3

Hormone Antagonists

Phase 3

Antiemetics

Phase 3

Tubulin Modulators

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Immunoglobulins

Phase 2, Phase 3

Antibodies

Phase 2, Phase 3

Antibodies, Monoclonal

Phase 2, Phase 3

HIV Protease Inhibitors

Phase 3

BB 1101

Phase 3

Interventional clinical trials:

(show top 50) (show all 223)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer	Active, not recruiting	NCT03691441	Phase 4	Chemotherapy
2	Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer	Completed	NCT01434394	Phase 2, Phase 3	Neo-adjuvant Erbitux-based chemotherapy
3	Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)	Completed	NCT00964977	Phase 3
4	Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia	Completed	NCT01874587	Phase 3
5	Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma	Completed	NCT00158652	Phase 3	5FU, Paraplatin
6	Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma	Completed	NCT00158678	Phase 3	concomitant cisplatin
7	A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
8	Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma	Completed	NCT03269344	Phase 3	Gabapentin;Placebo Oral Capsule
9	Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx	Completed	NCT00003627	Phase 3	cisplatin;fluorouracil
10	Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck	Recruiting	NCT01893307	Phase 2, Phase 3
11	A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer	Recruiting	NCT04648020	Phase 2, Phase 3	Clonidine HCl Mucoadhesive Buccal Tablet;Placebo Mucoadhesive Buccal Tablet
12	Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer	Recruiting	NCT04116047	Phase 3	Cisplatin;Durvalumab
13	Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy	Recruiting	NCT04019548	Phase 3	Cisplatin injection
14	A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer	Recruiting	NCT03952585	Phase 2, Phase 3	Cisplatin
15	A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer	Recruiting	NCT02215265	Phase 3	Cisplatin
16	Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial	Recruiting	NCT05369234	Phase 3	Carafate
17	A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC	Recruiting	NCT03811015	Phase 2, Phase 3	Cisplatin
18	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers	Recruiting	NCT05063552	Phase 2, Phase 3	Carboplatin;Cisplatin;Docetaxel
19	An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea	Active, not recruiting	NCT04189107	Phase 3	Dexamethasone;Placebo
20	The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer	Active, not recruiting	NCT01706939	Phase 3	Carboplatin
21	Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer	Active, not recruiting	NCT01302834	Phase 3	cisplatin
22	DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer	Active, not recruiting	NCT02908477	Phase 3	Docetaxel;Cisplatin
23	Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin	Active, not recruiting	NCT03258554	Phase 2, Phase 3
24	Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial	Not yet recruiting	NCT05144100	Phase 2, Phase 3	Cisplatin based chemotherpay
25	SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial	Not yet recruiting	NCT05451004	Phase 3
26	Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401)	Terminated	NCT00537199	Phase 3	OraTest
27	Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer	Terminated	NCT01066741	Phase 3	Homeodent®;1.4% Sodium Bicarbonate solution
28	Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer	Unknown status	NCT02960724	Phase 2
29	Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx	Unknown status	NCT01516996	Phase 2	docetaxel and cisplatin
30	Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer	Unknown status	NCT01932697	Phase 2	Docetaxel
31	Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]	Completed	NCT00064103	Phase 1, Phase 2
32	Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer	Completed	NCT00006360	Phase 1, Phase 2	radioprotection
33	Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer	Completed	NCT01032928	Phase 2
34	Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer	Completed	NCT03258008	Phase 2	Utomilumab
35	Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer	Completed	NCT01440270	Phase 2	Neo-adjuvant Erbitux-based chemotherapy
36	A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer	Completed	NCT02159703	Phase 2
37	A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers	Completed	NCT02280811	Phase 1, Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
38	Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment	Completed	NCT00780312	Phase 2
39	Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma	Completed	NCT01695122	Phase 2	Valproic Acid
40	Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy	Completed	NCT04251949	Phase 2
41	A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Completed	NCT03422536	Phase 2	Ficlatuzumab
42	Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial	Completed	NCT00330382	Phase 2	Bowman-Birk inhibitor concentrate
43	Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial)	Completed	NCT01733797	Phase 2
44	A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers	Completed	NCT01585428	Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
45	Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis	Completed	NCT01806675	Phase 1, Phase 2	18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
46	Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer	Completed	NCT01469429	Phase 1, Phase 2	chemoprevention
47	A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab	Completed	NCT01435252	Phase 2	Cetuximab
48	Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.	Completed	NCT01173692	Phase 2	Minocycline;Placebo
49	A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy	Completed	NCT03096808	Phase 2
50	Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer	Completed	NCT01108042	Phase 1, Phase 2	Taxotere, Cisplatin, 5-Fluorouracil (5-FU)

Search NIH Clinical Center for Oropharynx Cancer

Sources

Genetic Tests for Oropharynx Cancer

Sources

Anatomical Context for Oropharynx Cancer

Organs/tissues related to Oropharynx Cancer:

FMA: The

MalaCards : Tonsil, Tongue, Lymph Node, T Cells, Colon, Endothelial, Salivary Gland

Sources

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 4604)

#	Title	Authors	PMID	Year
1	A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. ⁵³ ⁶²	Ranieri G...Ribatti D	17378915	2007
2	Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. ⁵³ ⁶²	Coutelle C...Cassaigne A	9050916	1997
3	Successful Hypoglossal Nerve Upper Airway Stimulator Implantation After Chemoradiotherapy for Oropharynx Malignancy Complicated by Mandibular Osteoradionecrosis. ⁶²	Hoshal SG...Fuller SC	33405965	2023
4	Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016). ⁶²	Sengayi-Muchengeti M...Sitas F	36054877	2023
5	Do Health-Seeking Populations Know the Link Between Human Papillomavirus and Oropharyngeal Cancer? A Cross-Sectional Study in a Nigerian Population. ⁶²	Adesina A...Michael G	33818212	2023
6	TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer. ⁶²	Thomson DJ...Hall E	36452431	2023
7	HPV impact on oropharyngeal cancer radiological staging: 7th vs 8th edition of AJCC TNM classification. ⁶²	Dal Cin E...Tirelli G	36375362	2023
8	External validation of a CT-based radiomics signature in oropharyngeal cancer: assessing sources of variation. ⁶²	Guevorguian P...Mattonen SA	36464179	2022
9	An interpretable machine learning prognostic system for risk stratification in oropharyngeal cancer. ⁶²	Omobolaji Alabi R...Makitie AA	36279655	2022
10	Erratum to Studying prognostic significance of cytic nodal metastasis in HPV-positive oropharyngeal cancer. ⁶²		36167479	2022
11	Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan. ⁶²	Yoshida T...Furukawa T	35491282	2022
12	Peeling Back the Curtain on Circulating HPV Tumor DNA as a Pretreatment Biomarker in Oropharyngeal Cancer. ⁶²	Liu JC	36301555	2022
13	Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. ⁶²	Rettig EM...Hanna GJ	36301568	2022
14	External validation of an MR-based radiomic model predictive of locoregional control in oropharyngeal cancer. ⁶²	Bos P...Castelijns JA	36460924	2022
15	The psychosocial experiences of human papillomavirus (HPV) positive oropharyngeal cancer patients following (chemo)radiotherapy: A systematic review and meta-ethnography. ⁶²	Matthews S...Watson E	35726440	2022
16	Intraoperative Use of Wide-Field Optical Coherence Tomography to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx. ⁶²	Badhey AK...Miles BA	36454583	2022
17	Prevalence and risk factors of retro-styloid lymph node metastasis in oropharyngeal carcinoma. ⁶²	Toya R...Oya N	35098812	2022
18	Prediction of extranodal extension in oropharyngeal cancer patients and carcinoma of unknown primary: value of metabolic tumor imaging with hybrid PET compared with MRI and CT. ⁶²	Nemmour A...Morand GB	36471046	2022
19	Correlation between radiologic and pathologic extranodal extension in HPV-associated oropharyngeal cancer: Systematic review. ⁶²	Morey T...Foreman A	36071683	2022
20	Low postoperative lymphocyte count increases risk of progression in human papillomavirus associated oropharyngeal cancer. ⁶²	Yin LX...Van Abel KM	36129387	2022
21	Simultaneously Integrated Boost Affects Survival in Locally Advanced p16-Negative Oropharyngeal Squamous Cell Carcinoma. ⁶²	DE Felice F...Tombolini V	36456162	2022
22	Volumetric staging in radiotherapy for oropharyngeal cancers. ⁶²	Miszczyk M...Tarnawski R	34628998	2022
23	Geriatric Pharmacotherapy Case Series: Thiazide-Induced Hypokalemia. ⁶²	Burka AT...Geiger DW	36461138	2022
24	Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. ⁶²	Fan KM...Johnson NW	36247925	2022
25	The College of American Pathologists Foundation's See, Test & Treat Program®: an Evaluation of a One-Day Cancer Screening Program Implemented in Mississippi. ⁶²	Williams MS...Allen TC	34164764	2022
26	Surgical salvage of human papillomavirus-positive oropharyngeal cancer: Secondary analysis of a randomized controlled trial. ⁶²	Quan DL...Cramer JD	36401615	2022
27	Dynamic nomogram for long-term survival in patients with locally advanced oropharyngeal cancer after (chemo)radiotherapy. ⁶²	De Felice F...Guerrero Urbano T	36427081	2022
28	Raman spectroscopy in oral cavity and oropharyngeal cancer: a systematic review. ⁶²	Faur CI...Hedesiu M	35282942	2022
29	Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans. ⁶²	Chidambaram S...Massa ST	36191478	2022
30	Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints. ⁶²	Lee CT...Galloway TJ	36252636	2022
31	Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. ⁶²	Gormley M...Conway DI	36369568	2022
32	Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. ⁶²	Nishikawa D...Hanai N	36428754	2022
33	Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. ⁶²	Lee HI...Eom KY	36173618	2022
34	Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. ⁶²	Konuthula N...Barber BR	35930296	2022
35	Prevalence of Human Papillomavirus and Co-Infection with Epstein-Barr Virus in Oral and Oropharyngeal Squamous Cell Carcinomas. ⁶²	Makvandi M...Mirzaei H	36444607	2022
36	Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort. ⁶²	Liu Y...White DL	36378845	2022
37	Two-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurrent Radiation Therapy and Cisplatin for Head and Neck Cancer. ⁶²	Anderson CM...Sonis ST	35724774	2022
38	Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. ⁶²	de Jong BA...Both S	36373893	2022
39	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. ⁶²	Youssef I...Lee NY	36367724	2022
40	Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS). ⁶²	Garas G...Fleming JC	35842533	2022
41	Correction: Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. ⁶²	Bhatt KH...Khanna R	36282237	2022
42	Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. ⁶²	Zeng PYF...Nichols AC	36442320	2022
43	Impact of Alcohol and Smoking on Outcomes of HPV-Related Oropharyngeal Cancer. ⁶²	Lai YH...Tsai YS	36362736	2022
44	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. ⁶²	Robbins HA...Brennan P	35700419	2022
45	DNA hypermethylation of CADM1, PAX5, WT1, RARβ, and PAX6 genes in oropharyngeal cancer associated with human papillomavirus. ⁶²	Birknerova N...Chmelarova M	34974810	2022
46	Oropharyngeal cancer associated with sarcopenic obesity and sarcopenic weight loss. ⁶²	Manjusha M...Saravanan M	36058059	2022
47	Corrigendum to "Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharynx cancer: A multi-centre study" [Radiother. Oncol. 172 (2022) 111-117]. ⁶²	Price JM...Thomson DJ	36395551	2022
48	The Current Burden of Oropharyngeal Cancer: A Global Assessment Based on GLOBOCAN 2020. ⁶²	Lorenzoni V...Vaccarella S	36173880	2022
49	Triple variation in the vascular supply in the neck of a female donor body: a case report. ⁶²	Sanderson J...Bhattacharya A	36242606	2022
50	Oncogenic viruses as etiological risk factors for head and neck cancers: An overview on prevalence, mechanism of infection and clinical relevance. ⁶²	Payaradka R...Devegowda D	36049431	2022

Sources

Genes for Oropharynx Cancer

Genes related to Oropharynx Cancer (0 elite genes):

(show all 48)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ADH1C	Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide	Protein Coding	10.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9050916
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	8.61	DISEASES inferred ¹⁴
3	NFIB	Nuclear Factor I B	Protein Coding	8.29	DISEASES inferred ¹⁴
4	MIR21	MicroRNA 21	RNA Gene	7.84	DISEASES inferred ¹⁴ ¹⁴
5	H2AC18	H2A Clustered Histone 18	Protein Coding	7.62	DISEASES inferred ¹⁴ ¹⁴
6	TP53	Tumor Protein P53	Protein Coding	7.6	DISEASES inferred ¹⁴
7	MIR93	MicroRNA 93	RNA Gene	7.32	DISEASES inferred ¹⁴ ¹⁴
8	EGFR	Epidermal Growth Factor Receptor	Protein Coding	7.24	DISEASES inferred ¹⁴
9	MYBL1	MYB Proto-Oncogene Like 1	Protein Coding	7.14	DISEASES inferred ¹⁴
10	MIR486-1	MicroRNA 486-1	RNA Gene	7.07	DISEASES inferred ¹⁴ ¹⁴
11	MIR99A	MicroRNA 99a	RNA Gene	7.04	DISEASES inferred ¹⁴ ¹⁴
12	SERPINA3	Serpin Family A Member 3	Protein Coding	7.02	DISEASES inferred ¹⁴ ¹⁴
13	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.97	DISEASES inferred ¹⁴
14	MAML2	Mastermind Like Transcriptional Coactivator 2	Protein Coding	6.96	DISEASES inferred ¹⁴
15	MIR193B	MicroRNA 193b	RNA Gene	6.93	DISEASES inferred ¹⁴ ¹⁴
16	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.86	DISEASES inferred ¹⁴
17	CRTC1	CREB Regulated Transcription Coactivator 1	Protein Coding	6.8	DISEASES inferred ¹⁴
18	MIR196A1	MicroRNA 196a-1	RNA Gene	6.77	DISEASES inferred ¹⁴ ¹⁴
19	GP5	Glycoprotein V Platelet	Protein Coding	6.76	DISEASES inferred ¹⁴
20	CD274	CD274 Molecule	Protein Coding	6.71	DISEASES inferred ¹⁴
21	MIR130A	MicroRNA 130a	RNA Gene	6.69	DISEASES inferred ¹⁴ ¹⁴
22	KRT7	Keratin 7	Protein Coding	6.68	DISEASES inferred ¹⁴
23	KRT5	Keratin 5	Protein Coding	6.66	DISEASES inferred ¹⁴
24	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.66	DISEASES inferred ¹⁴
25	TYMP	Thymidine Phosphorylase	Protein Coding	6.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17378915
26	CDH1	Cadherin 1	Protein Coding	6.6	DISEASES inferred ¹⁴
27	NOTCH1	Notch Receptor 1	Protein Coding	6.59	DISEASES inferred ¹⁴
28	NTRK3	Neurotrophic Receptor Tyrosine Kinase 3	Protein Coding	6.52	DISEASES inferred ¹⁴
29	MIR1307	MicroRNA 1307	RNA Gene	6.51	DISEASES inferred ¹⁴ ¹⁴
30	MIR139	MicroRNA 139	RNA Gene	6.51	DISEASES inferred ¹⁴ ¹⁴
31	ETV6	ETS Variant Transcription Factor 6	Protein Coding	6.45	DISEASES inferred ¹⁴
32	PLAG1	PLAG1 Zinc Finger	Protein Coding	6.44	DISEASES inferred ¹⁴
33	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	6.4	DISEASES inferred ¹⁴ ¹⁴
34	CCND1	Cyclin D1	Protein Coding	6.4	DISEASES inferred ¹⁴
35	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.39	DISEASES inferred ¹⁴
36	MIR199A1	MicroRNA 199a-1	RNA Gene	6.32	DISEASES inferred ¹⁴ ¹⁴
37	CD8A	CD8a Molecule	Protein Coding	6.3	DISEASES inferred ¹⁴
38	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.22	DISEASES inferred ¹⁴
39	KRT14	Keratin 14	Protein Coding	6.21	DISEASES inferred ¹⁴
40	CTNNB1	Catenin Beta 1	Protein Coding	6.13	DISEASES inferred ¹⁴
41	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.08	DISEASES inferred ¹⁴
42	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.07	DISEASES inferred ¹⁴
43	UBE3A	Ubiquitin Protein Ligase E3A	Protein Coding	6.05	DISEASES inferred ¹⁴
44	ESR1	Estrogen Receptor 1	Protein Coding	6.02	DISEASES inferred ¹⁴
45	CD4	CD4 Molecule	Protein Coding	6.02	DISEASES inferred ¹⁴
46	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.01	DISEASES inferred ¹⁴
47	PGR	Progesterone Receptor	Protein Coding	6	DISEASES inferred ¹⁴
48	EGF	Epidermal Growth Factor	Protein Coding	5.97	DISEASES inferred ¹⁴

Sources

Variations for Oropharynx Cancer

Sources

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Sources

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.34	TP53 KIT ERBB2 EGFR CDKN2A
2	Malignant pleural mesothelioma ⁷⁴	12.27	TP53 KIT EGFR CDKN2A CD274
3	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.19	TP53 KIT ERBB2 EGFR
4	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.56	KIT ERBB2 EGFR
5	AP-1 transcription factor network ⁶¹	11.42	TP53 CRTC1 CDKN2A
6	miRNAs involved in DNA damage response ⁷⁴	11.37	TP53 MIR93 MIR21
7	Head and neck squamous cell carcinoma ⁷⁴	11.32	TP53 ERBB2 EGFR CDKN2A
8	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.05	TP53 NFIB MYBL1 ERBB2
9	Bladder cancer ⁷⁴	10.53	TP53 ERBB2 EGFR CDKN2A

Sources

GO Terms for Oropharynx Cancer

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of miRNA maturation	GO:1903800	9.16	TP53 EGFR
2	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.13	ERBB2 CDKN2A
3	positive regulation of vascular associated smooth muscle cell differentiation	GO:1905065	8.8	MIR21 KIT

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.43	TP53 MIR93 MIR486-1 MIR21 MIR193B
2	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR99A MIR93 MIR486-1 MIR21 MIR196A1 MIR193B